US Patent 11,446,291: Scope, Enforceability, and Patent Landscape for Tetrabenazine-to-Deutetrabenazine Switching
US Patent 11,446,291 protects a narrow, regimen-specific method for switching a patient with tardive dyskinesia from tetrabenazine to deutetrabenazine. The patent does not broadly cover deutetrabenazine, Austedo, tetrabenazine, or treatment of tardive dyskinesia. Its commercial significance comes from the overlap between the claimed switching protocol and FDA-approved dosing instructions for deutetrabenazine.
The core protection requires:
- Discontinuing tetrabenazine.
- Starting deutetrabenazine the next day.
- Using one of eight specified dose conversions.
- Applying the method to a human being treated for tardive dyskinesia.
- In dependent claims, administering deutetrabenazine in two daily doses.
- Titrating by 6 mg/day at approximately weekly intervals based on efficacy and tolerability.
- Limiting the maximum dose to 48 mg/day or 36 mg/day in specified circumstances.
- Using a 36 mg/day maximum when the patient receives a strong CYP2D6 inhibitor.
The principal risk is label-based infringement. If a generic or authorized generic uses FDA labeling that instructs patients to make the claimed switch, the patent holder may assert induced infringement under 35 U.S.C. § 271(b), even though the patent claims a method of treatment rather than the drug product itself.
What does US Patent 11,446,291 claim?
Claim 1 is the only independent claim. It defines a dose-conversion table:
| Daily tetrabenazine dose |
Next-day deutetrabenazine starting dose |
| 12.5 mg |
6 mg |
| 25 mg |
12 mg |
| 37.5 mg |
18 mg |
| 50 mg |
24 mg |
| 62.5 mg |
30 mg |
| 75 mg |
36 mg |
| 87.5 mg |
42 mg |
| 100 mg |
48 mg |
The claim requires an immediate next-day transition. A protocol involving a washout period, overlapping therapy, or a delayed start may fall outside claim 1 unless another claim limitation is met through an equivalent or modified regimen.
The claim also requires treatment of tardive dyskinesia. A transition performed solely for Huntington’s disease chorea, without the claimed tardive dyskinesia indication, would not literally satisfy that limitation.
How narrow is the independent claim?
Claim 1 is narrow in four important respects:
- It is limited to a human patient.
- It is limited to tardive dyskinesia.
- It requires discontinuation of tetrabenazine followed by deutetrabenazine the next day.
- It covers only eight expressly listed dose pairs.
A regimen beginning with 9 mg/day of deutetrabenazine, for example, is outside the literal dose list in claim 1. A switch from tetrabenazine 25 mg/day to deutetrabenazine 18 mg/day also falls outside the listed conversion pairs unless another claim theory applies.
The claim is stronger against standardized conversion protocols than against individualized, off-label regimens that avoid one or more listed dose pairs.
What dependent claims add to the patent scope?
Claims 2 through 30 add administration schedules, titration rules, dose reductions, and maximum-dose restrictions.
| Claims |
Added limitation |
Commercial significance |
| 2-3 |
Two daily doses; equal split of the initial dose |
Captures common twice-daily administration |
| 4-7 |
Weekly assessment, 6 mg/day upward titration, tolerability-based adjustment |
Protects the titration algorithm |
| 8-10 |
Repeated weekly assessment and escalation to specified doses |
Covers an iterative maintenance protocol |
| 11 |
Maximum daily dose of 48 mg |
Relevant to higher-dose regimens |
| 12 |
Maximum daily dose of 36 mg |
Relevant to tardive dyskinesia and CYP2D6 restrictions |
| 13-15 |
Concurrent strong CYP2D6 inhibitor |
Targets fluoxetine, paroxetine, bupropion, quinidine, cinacalcet, and ritonavir |
| 16-30 |
Individual dose-pair embodiments |
Creates multiple fallback positions for enforcement |
Claims 16 through 30 separately recite the eight dose conversions, with claims 18, 20, 22, 24, 26, 28, and 30 adding equal twice-daily administration.
The dependent claims improve litigation flexibility. Even if a court narrows claim 1, individual dose-pair claims may remain relevant where the accused protocol uses a specific listed conversion.
What is the patent’s technical contribution?
The claimed method uses a roughly 2:1 conversion relationship between tetrabenazine and deutetrabenazine:
[
\text{Initial deutetrabenazine dose} \approx 0.48 \times \text{tetrabenazine dose}
]
The conversion is not a simple milligram-for-milligram substitution. Deutetrabenazine is a deuterated form of tetrabenazine designed to alter metabolic behavior and exposure. The patent claims the clinical implementation of the switch rather than the underlying chemical composition.
Its technical focus is therefore operational:
- avoid a prolonged treatment interruption;
- start the deuterated product the day after tetrabenazine discontinuation;
- preserve control of abnormal involuntary movement;
- adjust the dose at approximately one-week intervals;
- reduce the dose by 6 mg/day when tolerability becomes inadequate.
The claims do not require a particular tablet strength, manufacturer, formulation technology, pharmacokinetic result, or clinical rating scale. The relevant product must be administered in a manner that satisfies the claimed dose and timing limitations.
What formulations are protected by US 11,446,291?
US 11,446,291 is not principally a formulation patent. It does not claim:
- a tablet composition;
- a capsule composition;
- a specific crystal form;
- a particular excipient;
- a sustained-release formulation;
- a specific deutetrabenazine stereoisomer;
- a manufacturing process; or
- a particular tablet-strength combination.
The claims are dosage-method claims. A generic product can infringe regardless of whether it uses a different excipient system or manufacturing process, if the product is promoted or administered according to the claimed switching method.
A formulation patent could create a separate barrier, but formulation differences would not by themselves avoid a method claim.
When does US Patent 11,446,291 expire?
The patent issued on September 20, 2022. Its enforceable term is governed by the patent-term rules in 35 U.S.C. § 154, including the 20-year term measured from the applicable nonprovisional or international filing date and any patent-term adjustment.
The exact expiration date cannot be established from the claim text alone. The controlling record is the USPTO patent-data record, including:
- earliest effective nonprovisional filing date;
- patent-term adjustment;
- terminal disclaimers;
- any patent-term extension;
- reexamination or post-grant changes.
Based on the 2022 issue date and the apparent priority structure of the switching-method application, the nominal term is expected to run into the late 2030s, subject to the USPTO-calculated expiration date. The patent should therefore be treated as a long-dated method-of-use asset rather than a near-term expiring right.
What is the FDA and Orange Book relevance?
Austedo, the commercial deutetrabenazine product, is FDA-approved for chorea associated with Huntington’s disease and tardive dyskinesia. The FDA prescribing information includes dose-initiation, titration, administration-frequency, and CYP2D6-related restrictions that overlap with the patent claims.[1]
The Orange Book distinction is important:
- Product patents and formulation patents are typically listed against the approved drug product.
- Method-of-use patents may be listed when they claim an approved use and satisfy FDA listing requirements.
- An Orange Book listing does not establish validity or infringement.
- A generic applicant must address listed patents through a Paragraph IV certification, a Paragraph III certification, or a section viii statement, depending on the patent and the proposed labeling.[2]
If US 11,446,291 is listed for the relevant Austedo product, an ANDA applicant may face a 30-month stay after a timely Paragraph IV notice and patent litigation under the Hatch-Waxman framework. If the patent is not listed, the holder may still pursue infringement litigation, but the automatic regulatory stay mechanism may not apply.
The practical issue is whether a generic label would encourage the claimed switching method. A section viii carve-out may be difficult if the switching instructions are embedded in the approved labeling for tardive dyskinesia rather than presented as a separately removable indication.
How does the patent interact with the FDA-approved dosing regimen?
The overlap is substantial.
The patent claims:
- next-day initiation;
- specified conversion doses;
- twice-daily administration;
- escalation by 6 mg/day;
- weekly reassessment;
- dose reduction for intolerance;
- 36 mg/day and 48 mg/day maximums;
- CYP2D6 inhibitor restrictions.
These are ordinary elements of a labeled treatment protocol rather than an unusual research-use regimen. That increases the risk that a product label, physician instruction, pharmacist counseling, or patient-support program could be used as evidence of induced infringement.
The strongest overlap exists where a label or promotional material expressly states that patients taking tetrabenazine may discontinue it and initiate deutetrabenazine the next day at a specified dose.
What are the main Paragraph IV risks?
A generic applicant challenging an Orange Book listing would likely evaluate four principal defenses.
Anticipation
The applicant would search for prior art disclosing:
- switching from tetrabenazine to deutetrabenazine;
- next-day initiation;
- the specific 2:1 dose-conversion table;
- twice-daily dosing;
- 6 mg/day weekly titration; and
- use in tardive dyskinesia.
A reference that discloses only deutetrabenazine dosing, without the tetrabenazine transition, may not anticipate claim 1. A reference that discloses a general switch but not the exact dose pairs may face a similar limitation.
Obviousness
Obviousness is likely the central validity issue. The applicant may argue that a skilled clinician would have combined:
- the known pharmacology of tetrabenazine;
- the approved starting doses for deutetrabenazine;
- the known 6 mg dose increments;
- the known maximum doses; and
- standard clinical switching practice.
The patent holder would counter that the exact conversion table, next-day timing, maintenance of chorea or abnormal-movement control, and tolerability-based titration were not predictable as a package.
Written description and enablement
The detailed dose table and titration procedure provide substantial written-description support for the issued claims. A broader challenge could focus on whether the specification supports every combination of:
- tetrabenazine dose;
- deutetrabenazine dose;
- twice-daily administration;
- CYP2D6 inhibitor use;
- maximum-dose limitations; and
- clinical response criteria.
The claims are sufficiently concrete that enablement challenges are likely to focus on scope across patient populations rather than on the existence of an operative protocol.
Indefiniteness
Potential construction issues include:
- the meaning of “about one week”;
- the meaning of “at least a maintenance of chorea control”;
- the meaning of “adequate” control;
- the meaning of “tolerable”; and
- whether “initial total daily amount” requires a particular first-day administration time.
These terms are clinical and functional. They may be construed in light of the specification and ordinary clinical practice, but they create factual disputes in infringement litigation.
What generic launch scenarios exist?
| Launch scenario |
Patent exposure |
Regulatory effect |
| Full label including switching instructions |
High |
Paragraph IV litigation risk; potential 30-month stay if listed |
| Label omitting tetrabenazine-switching language |
Lower for induced infringement |
Section viii strategy may be possible if FDA accepts the carve-out |
| Product sold without promotional switching instructions but used by physicians |
Direct method-infringement risk shifts toward prescribers and providers |
Commercial evidence becomes important |
| Launch after patent expiration |
No infringement risk from this patent |
Other product, formulation, or method patents may remain |
| At-risk launch after Paragraph IV challenge |
High damages and injunction exposure |
Depends on litigation outcome and patent-term status |
A generic can avoid some induced-infringement risk by removing switching instructions and related promotional material. That strategy may reduce the product’s clinical utility and complicate substitution for patients already receiving tetrabenazine.
Which companies are most exposed?
The principal commercial exposure falls on:
- the NDA holder and its affiliates;
- ANDA applicants seeking approval for deutetrabenazine;
- authorized generics;
- specialty pharmacies providing switching support;
- telemedicine providers using standardized transition protocols; and
- healthcare systems adopting conversion order sets.
The risk is highest for a company marketing a direct substitute for Austedo with labeling that reproduces the claimed conversion table. A company offering only a chemically different VMAT2 inhibitor would generally face no literal infringement of this patent because the claims require deutetrabenazine administration.
Valbenazine, marketed as Ingrezza, is a relevant commercial competitor but does not satisfy the express deutetrabenazine limitation. A valbenazine regimen should not literally infringe these claims.
How strong is the patent estate compared with competing VMAT2 products?
| Issue |
Deutetrabenazine / Austedo |
Valbenazine / Ingrezza |
| Claimed molecule in US 11,446,291 |
Deutetrabenazine |
Not covered |
| Claimed indication |
Tardive dyskinesia |
Not relevant to this patent |
| Claimed transition |
Tetrabenazine to deutetrabenazine |
Not covered |
| Main claim type |
Method of treatment |
Competing product has separate patent estate |
| Generic risk |
Highest for deutetrabenazine substitutes |
No direct risk from US 11,446,291 |
| Formulation relevance |
Limited in this patent |
Must be assessed separately |
| CYP2D6 limitation |
Expressly claimed in dependent claims |
Not applicable |
US 11,446,291 is a targeted barrier. It is not a complete exclusivity platform for deutetrabenazine. The broader commercial patent estate must be analyzed separately across composition, salt or crystal form, formulation, dosing, indication, and manufacturing patents.
Does the patent protect manufacturing or geographic markets?
No. The asserted claims do not claim manufacturing steps or pharmaceutical composition structure. They protect conduct involving treatment of a human.
US infringement generally requires conduct tied to the United States. Foreign manufacture of deutetrabenazine does not, by itself, infringe these method claims. US distribution, prescribing, administration, or encouragement of the claimed switching protocol may create exposure under the relevant statutory provisions.
Foreign markets require separate analysis of national counterparts, local patent-term rules, regulatory-label practices, and exhaustion principles. A US patent cannot be assumed to control Canadian, European, Japanese, or other market launches.
What litigation and licensing issues matter most?
The principal litigation issues are likely to be:
- Whether the patent is listed for the relevant Austedo product.
- Whether an ANDA applicant makes a valid Paragraph IV or section viii certification.
- Whether the proposed label encourages the claimed transition.
- Whether the dose table is anticipated or obvious.
- Whether “about one week” and tolerability-based limitations are definite.
- Whether the patent owner can prove induced infringement by the generic manufacturer.
- Whether any settlement permits a licensed date, authorized-generic launch, or label carve-out.
A settlement could include a delayed generic entry date, a license to practice the switching method, an authorized-generic arrangement, or restrictions on promotional materials. No settlement terms should be inferred from patent issuance or Orange Book listing alone.
Key Takeaways
- US Patent 11,446,291 is a narrow method-of-treatment patent covering specific next-day switches from tetrabenazine to deutetrabenazine.
- Claim 1 covers eight conversion pairs, from 12.5 mg tetrabenazine to 6 mg deutetrabenazine through 100 mg tetrabenazine to 48 mg deutetrabenazine.
- Dependent claims add twice-daily administration, weekly titration, 6 mg/day dose changes, tolerability adjustments, maximum doses, and CYP2D6 inhibitor use.
- The patent does not broadly claim deutetrabenazine, Austedo, a formulation, or a manufacturing method.
- The greatest commercial risk is induced infringement from a generic label or promotional program that reproduces the FDA-aligned switching protocol.
- A section viii label carve-out could reduce risk, but its availability depends on Orange Book listing status and FDA acceptance.
- Validity challenges are most likely to focus on obviousness, clinical predictability, and the patent’s functional terms.
- Exact expiration and Orange Book status must be taken from the current USPTO and FDA records, including any patent-term adjustment, terminal disclaimer, listing change, or litigation outcome.
FAQs About US Patent 11,446,291
Does switching from tetrabenazine to Austedo always infringe US Patent 11,446,291?
No. Infringement requires satisfaction of every relevant claim limitation. The dose pair, next-day timing, tardive dyskinesia treatment, administration schedule, and titration conduct must be evaluated together.
Is a 25 mg tetrabenazine to 12 mg deutetrabenazine switch covered?
Yes. That conversion is expressly recited in claim 1 and separately reinforced by claims 17 and 18 when the 12 mg dose is administered as two 6 mg doses.
Is a 25 mg tetrabenazine to 18 mg deutetrabenazine switch covered?
Not literally under the expressly listed dose pairs in claim 1. Other infringement theories would depend on the patent’s construction, the complete protocol, and the facts of use.
Does the patent cover Austedo XR?
The claims are directed to administering deutetrabenazine and do not expressly require a particular release profile or dosage form. Austedo XR exposure therefore depends on whether its active ingredient, dosing instructions, and labeled switching method satisfy the claim limitations.
Can a generic launch without the switching method?
Potentially. A generic applicant may seek approval with a label that omits the patented method if FDA regulations permit the carve-out. The applicant must also control promotional materials and other conduct that could be used to show encouragement of the patented regimen.
References
- U.S. Food and Drug Administration. (2024). Austedo (deutetrabenazine) prescribing information.
- U.S. Patent and Trademark Office. (2022). U.S. Patent No. 11,446,291.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- 35 U.S.C. §§ 154, 271, 281, 283, 284, 355.
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
